These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27299426)

  • 1. [Results of a Questionnaire-Based Study on Guideline Adherence Regarding Adjuvant Treatment Recommendations for Patients with Non-Muscle-Invasive Bladder Cancer: Just a Disturbing Sidelight?].
    Lebentrau S; Lebentrau J; May M; Wick AK; Mathew M; Schostak M
    Aktuelle Urol; 2016 Sep; 47(5):408-13. PubMed ID: 27299426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-muscle-invasive bladder cancer: Information transfer from the clinic to the doctor's office : Results of a questionnaire study and presentation of a software solution].
    Lebentrau S; May M; Weckermann D; Speck T; Wick AK; Mathew M; Schostak M
    Urologe A; 2017 Feb; 56(2):194-201. PubMed ID: 27637184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
    Hendricksen K; Aziz A; Bes P; Chun FK; Dobruch J; Kluth LA; Gontero P; Necchi A; Noon AP; van Rhijn BWG; Rink M; Roghmann F; Rouprêt M; Seiler R; Shariat SF; Qvick B; Babjuk M; Xylinas E;
    Eur Urol Focus; 2019 Jul; 5(4):681-688. PubMed ID: 29074050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.
    Matulay JT; Tabayoyong W; Duplisea JJ; Chang C; Daneshmand S; Gore JL; Holzbeierlein JM; Karsh LI; Kim SP; Konety BR; Li R; McKiernan JM; Messing EM; Steinberg GD; Williams SB; Kamat AM
    Urol Oncol; 2020 Oct; 38(10):796.e1-796.e6. PubMed ID: 32430255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study.
    Gontero P; Oderda M; Altieri V; Bartoletti R; Cai T; Colombo R; Curotto A; Di Stasi S; Maffezzini M; Tamagno S; Serretta V; Sogni F; Terrone C; Tizzani A; Morgia G; Mirone V; Carmignani G
    Urol Int; 2011; 86(1):19-24. PubMed ID: 21196690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
    Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey.
    Struck JP; Hennig MJP; Hupe MC; Moharam N; Paffenholz P; Nestler T; Frank T; Worst TS; Grabbert M; Pohlmann PF; Dogan S; Hofbauer SL; Kalogirou C; Mattigk A; Brandt MP; Krabbe LM; Reis H; Dressler FF; Kramer MW; Salem J
    Urol Int; 2023; 107(1):35-45. PubMed ID: 34515257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations.
    Zhang J; Wang Y; Weng H; Wang D; Han F; Huang Q; Deng T; Wang X; Jin Y
    BMC Cancer; 2019 Nov; 19(1):1054. PubMed ID: 31694589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we following the guidelines on non-muscle invasive bladder cancer?
    Reis LO; Moro JC; Ribeiro LF; Voris BR; Sadi MV
    Int Braz J Urol; 2016; 42(1):22-8. PubMed ID: 27136464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
    van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
    Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    Chang SS; Boorjian SA; Chou R; Clark PE; Daneshmand S; Konety BR; Pruthi R; Quale DZ; Ritch CR; Seigne JD; Skinner EC; Smith ND; McKiernan JM
    J Urol; 2016 Oct; 196(4):1021-9. PubMed ID: 27317986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project.
    Hurle R; Pasini L; Lazzeri M; Colombo P; Buffi N; Lughezzani G; Casale P; Morenghi E; Peschechera R; Zandegiacomo S; Benetti A; Saita A; Cardone P; Guazzoni G
    BJU Int; 2016 Dec; 118(6):935-939. PubMed ID: 27207387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
    Kausch von Schmeling I
    Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline of guidelines: non-muscle-invasive bladder cancer.
    Woldu SL; Bagrodia A; Lotan Y
    BJU Int; 2017 Mar; 119(3):371-380. PubMed ID: 28058776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
    Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
    Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.